Skip to main navigation

albireo_logo_nav.svg

  • About
    • Overview
    • Enterprise Team
    • Board of Directors
    • Partnering
    • Contact
  • Programs & Science
    • Bile Acids and IBAT Inhibition
    • Pipeline
    • Odevixibat
    • A3384
    • Elobixibat
  • Patients & Families
    • Progressive Familial Intrahepatic Cholestasis (PFIC)
    • ALAGILLE SYNDROME
    • BILIARY ATRESIA
    • Chronic (Idiopathic) Constipation
    • ADULT LIVER DISEASES
    • Bile Acid Malabsorption (BAM)
    • Clinical Trials
    • Expanded Use
  • Media & Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Publications
    • 2020 Annual Meeting
    • Corporate Governance
    • Stock Information
    • Financials & Filings
    • Analyst Coverage
    • Contact Us
  • Careers
    • Current Openings

Financials & Filings

Financials menu

  • Financials & Filings
    • SEC Filings
    • Annual Reports and Proxies
    • Quarterly Reports
    • Key Ratios

Stock Information menu

  • Stock Information

governance menu

  • Corporate Governance

Show all

2020

Q4
  • Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update
  • Form 10-K

Proxy Statements

Apr 17, 2020
View HTML
0001047469-20-002399.pdf
0001047469-20-002399.xls


Apr 25, 2019
View HTML
0001047469-19-002577.pdf
0001047469-19-002577.xls


Form 10-K

Feb 25, 2021
View HTML
0001558370-21-001730.pdf
0001558370-21-001730.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA


Mar 02, 2020
View HTML
0001558370-20-001905.pdf
0001558370-20-001905.xls
EX-101.INS - EX-101.INS


Form 10-Q

Nov 05, 2020
View HTML
0001558370-20-012727.pdf
0001558370-20-012727.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA


Aug 06, 2020
View HTML
0001558370-20-009519.pdf
0001558370-20-009519.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA


Shareholder Tools

  • Email Alerts

    Email Alerts

  • RSS

    RSS

  • Print

    Print

 
albireo-white

© 2018 Albireo Pharma, Inc.

Contact |  Terms of Use  |  Privacy Policy      twitter